Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04989335 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT04989335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Sheba Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
August 2, 2021
Completion date
December 1, 2025
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelogenous leukemia, acute